Efgartigimod alfa targets FcRn across three neuroimmune conditions
New drug shows promise for rare autoimmune nerve conditions
Efgartigimod alfa blocks FcRn to lower circulating IgG. It is approved for myasthenia gravis and CIDP, but not Guillain-Barré syndrome.
A new medication targets the immune system to treat rare nerve conditions, though it is not yet approved for all patients.
Case report and review: IVIg and efgartigimod in Guillain-Barré with Graves disease and thyroid cancer
Doctors treat a rare relapse of Guillain-Barré syndrome with new immune therapies
This case report and literature review describes a 33-year-old man with Guillain-Barré syndrome, Graves disease, and papillary thyroid carci…
A 33-year-old man with Guillain-Barré syndrome found relief after doctors treated his underlying thyroid cancer and used new immune therapie…
Review of Hepatitis E Virus Associated Neurological Injury Syndromes
Hepatitis E virus may be linked to several rare neurological conditions
This review examines the association between Hepatitis E virus (HEV) exposure and specific neurological conditions, including Guillain–Barré…
A review suggests Hepatitis E virus might connect to rare neurological issues like Guillain–Barré syndrome, though more research is needed t…
Narrative review examines immunotherapy options for anti-GQ1b antibody syndromes including BBE and Miller Fisher syndrome
A Rare Brainstem Condition Has a New Diagnostic Map
This narrative review evaluates the role of immunotherapy in patients with anti-GQ1b antibody syndromes, including Bickerstaff Brainstem Enc…
A new model groups rare brain disorders causing double vision and balance problems into one clear spectrum to help doctors diagnose confusin…
Efgartigimod showed higher independent walking at week 4 and running at week 12 versus IVIG in GBS patients unable to walk
A Newer Drug Outperformed the Standard Treatment for a Paralyzing Nerve Disease
This single-center retrospective study evaluated efgartigimod versus intravenous immunoglobulin (IVIG) in 34 Guillain-Barré syndrome patient…
A newer drug helped 100% of paralyzed Guillain-Barré patients walk again in four weeks, outperforming the standard treatment in a recent stu…